Appointments

The Canada Foundation for Innovation (CFI) announces the appointment of Dr. Albert Friesen to the CFI Board of Directors. Albert D. Friesen holds a Ph.D. in protein chemistry from the University of Manitoba. He has been

instrumental in the founding and development of several health industry companies, including Apotex Fermentation, and the development of Canada’s first biotech product, WinRho. Dr. Friesen is a founder of BIOTECanada. He is currently president and CEO of Medicure Inc. and president of Genesys Venture Inc. Dr. Friesen led the establishment of CentreStone Venture Partners, a $22 million life sciences fund based in Winnipeg, and currently serves on the Premier’s Economic Advisory Council.

Hamilton Thorne Ltd. announces the appointment of Michelle Lyles, Ph.D., to the role of vice president of Sales. Lyles will be responsible for managing Hamilton Thorne’s worldwide sales initiatives and will oversee the company’s sales team and distributor relationships. “Dr. Lyles’ experience in product positioning and marketing novel technologies to the life science research market and her track record in leading successful sales teams will greatly expand the reach of Hamilton Thorne,” says Meg Spencer, chairman and CEO of Hamilton Thorne. Dr. Lyles brings more than 15 years of experience in progressively senior Sales and Marketing roles for life science research companies. Most recently, she was vice president of Marketing and Sales at febit, inc, a developer of automated solutions for enabling biochip applications in Life Sciences.

Dr. Albert Friesen

OncoGenex Pharmaceuticals, Inc. has appointed Dr. Jack Goldstein and Ms. H. Stewart Parker to its board of directors. In addition, Dr. Martin Mattingly has agreed to stand for election at the company’s

H. Stewart Parker

upcoming Annual General Meeting. Dr. Goldstein joins the board as chairman. The new board members add substantial pharmaceutical industry experience as former chief executive officers, presidents and/or directors for several pharmaceutical companies. Dr. Goldstein served as president and chief operating officer of Chiron Corporation until its acquisition by Novartis in April 2006. H. Stewart Parker served as president, chief executive officer and director of Targeted Genetics Corporation, a position she held since managing its formation and spinout from Immunex Corporation in 1992. Martin A. Mattingly, Pharm.D., is the chief executive officer and member of the board of directors of Trimeris, Inc. Martin most recently served as president and chief executive officer at Ambrx, Inc.

DiagnoCure, Inc. has appointed Valerie Palmieri as president of DiagnoCure Oncology Laboratories, the U.S. subsidiary of DiagnoCure, Inc. Palmieri brings to DiagnoCure more than 25 years of experience in the laboratory industry, including executive positions responsible for laboratory services, business strategic planning, cost management, quality, customer retention and operations management. Palmieri held several executive positions at DIANON Systems and Laboratory Corporation of America. While leading operations for the anatomic pathology, genetics and esoteric clinical pathology businesses, she played an instrumental role in driving growth and optimizing profitability. In other executive positions, she led implementation of a company-wide customer retention program, successfully integrated two major acquisitions, and launched several new diagnostic services and products. For the past year, Palmieri served as a consultant with Momentum Consulting, which specializes in healthcare solutions.

Stellar Pharmaceuticals Inc. announces that Steven H. Goldman has rejoined its Board of Directors.

Goldman is an accomplished lawyer, business leader and currently a partner in the Toronto law firm of Goldman Hine LLP. Before joining that firm, he successfully led the restructuring and turnaround of the Speedy Auto Service and Minute Muffler franchise systems as their president and CEO from December 2007 until December 2009. Peter Riehl, Stellar’s president and chief executive officer, commented, “We are very pleased to have Steven rejoin our Board and Audit Committee at this important time in our company’s development. His great business accomplishments, combined with his senior legal experience, will be a tremendous asset to Stellar as we work toward building our Canadian business and expanding the global licensing of Uracyst® and NeoVisc®.”

Valerie Palmieri

Steven H. Goldman